Breaking News Instant updates and real-time market news.

LMT

Lockheed Martin

$303.75

0.5 (0.16%)

, RTN

Raytheon

$179.35

1.73 (0.97%)

13:45
08/12/17
08/12
13:45
08/12/17
13:45

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. DEFENSE SECTOR: Defense stocks rallied on Wednesday, a day after President Donald Trump warned that threats from North Korea "will be met with fire and fury." However, the rest of the market fell on concerns about increased geopolitical tensions in the area. Publicly traded companies in the sector include Lockheed Martin (LMT), Raytheon (RTN), Northrop Grumman (NOC) and L3 Technologies (LLL). 2. MISSILE DEFENSE: According to a report by Reuters, citing the company's VP of Air and Missile Defense business, Lockheed Martin is seeing a greater interest in missile defense systems as customers want to defend against potential incoming missile attacks amid a rise in North Korean long-range missile tests. Cahill said that interest in missile defense has increased over the last 12 to 18 months, which could result in sales in the coming years. Meanwhile, Baird analyst Peter Arment raised Raytheon's price target to $212 from $170 this week to reflect significant program wins both domestically and internationally for missile defense and missile systems that puts the company in position for favorable organic growth in 2018 and beyond. 3. BACK TO WORK, MITCH: On Thursday, President Trump tweeted, "Mitch, get back to work and put Repeal & Replace, Tax Reform & Cuts and a great Infrastructure Bill on my desk for signing. You can do it!" Hours later, in response to a question about whether Senate Majority Leader Mitch McConnell should step down, President Trump said, "If he doesn't get repeal and replace [of ObamaCare] done, and if he doesn't get taxes done, meaning cuts and reform, and if he doesn't get a very easy one to get done, infrastructure, if he doesn't get them done, then you can ask me that question," according to Fox News. Publicly traded companies in the health insurance space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

LMT

Lockheed Martin

$303.75

0.5 (0.16%)

RTN

Raytheon

$179.35

1.73 (0.97%)

NOC

Northrop Grumman

$269.28

-1.27 (-0.47%)

LLL

L3 Technologies

$183.63

0.34 (0.19%)

AET

Aetna

$152.15

-0.27 (-0.18%)

ANTM

Anthem

$189.43

-0.29 (-0.15%)

CNC

Centene

$82.14

0.73 (0.90%)

CI

Cigna

$174.38

-0.98 (-0.56%)

HNT

Health Net

HUM

Humana

$249.99

-1.68 (-0.67%)

MOH

Molina Healthcare

$58.05

0.52 (0.90%)

UNH

UnitedHealth

$193.02

0.45 (0.23%)

WCG

WellCare

$172.39

0.36 (0.21%)

  • 14

    Aug

  • 23

    Aug

  • 26

    Sep

  • 27

    Sep

  • 08

    Nov

LMT Lockheed Martin
$303.75

0.5 (0.16%)

08/08/17
08/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN), Alphabet (GOOG, GOOGL), and Facebook (FB) were reinstated with a Buy at Mizuho, while eBay (EBAY) and Twitter (TWTR) were reinstated with an Underperform. 2. Broadridge (BR) initiated with a Neutral at DA Davidson. 3. Brighthouse Financial (BHF) initiated with an Overweight at Barclays. 4. Akcea Therapeutics (AKCA) WAS initiated with an Outperform at BMO Capital and Cowen, an Outperform at Wells Fargo, as well as a Buy at Stifel. 5. Lockheed Martin (LMT) and Raytheon (RTN) were initiated with an Overweight at Morgan Stanley, while Northrop Grumman (NOC) was initiated with an Equal Weight, and General Dynamics (GD) was initiated with an Underweight at the firm. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/17
MSCO
08/08/17
INITIATION
Target $342
MSCO
Overweight
Lockheed Martin initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated Lockheed Martin with an Overweight and a $342 price target saying it has the right balance of segment margin growth, revenue visibility, and leading 5-year CAGR, all supported by the F-35 ramp over the coming years, combined with pension benefits.
07/19/17
ARGS
07/19/17
NO CHANGE
ARGS
Lockheed Martin price target raised to $320 from $290 at Argus
Argus analyst John Eade increased his price target on Lockheed Martin after the company reported higher than expected Q2 EPS. The analyst notes that U.S. defense spending is rising, while geopolitical tensions are increasing. Calling the stock's valuation attractive, he keeps a Buy rating on the shares.
07/19/17
FBCO
07/19/17
NO CHANGE
Target $300
FBCO
Neutral
Lockheed Martin price target raised to $300 from $280 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Lockheed Martin to $300 from $280 as he expects shares to grind higher with continued earnings growth, perhaps tempered a little by flattish CF largely due to contract timing. He reiterates a Neutral rating on the shares.
RTN Raytheon
$179.35

1.73 (0.97%)

08/10/17
BARD
08/10/17
NO CHANGE
Target $212
BARD
Outperform
Raytheon price target raised to $212 from $170 at Baird
Baird analyst Peter Arment raised his price target on Raytheon to $212 from $170 to reflect significant program wins both domestically and internationally for missile defense and missile systems that puts the company in position for favorable organic growth in 2018 and beyond. Arment reiterated his Outperform rating on Raytheon shares.
08/08/17
MSCO
08/08/17
INITIATION
Target $188
MSCO
Overweight
Raytheon initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated Raytheon with an Overweight and a $188 price target saying it has leading positions in high demand areas of missile defense and internationally, and optionality around an A-rated balance sheet.
08/04/17
ARGS
08/04/17
NO CHANGE
ARGS
Raytheon price target raised to $195 from $175 at Argus
Argus analyst John Eade raised his price target on Raytheon after the company reported stronger than expected Q2 results and raised its 2017 guidance. The analyst keeps a Buy rating on the shares.
NOC Northrop Grumman
$269.28

-1.27 (-0.47%)

04/18/17
RBCM
04/18/17
NO CHANGE
RBCM
Defense stocks should be bought on any weakness, says RBC Capital
RBC Capital analyst Matthew McConnell,recommends buying defense stocks on any weakness caused by near-term funding uncertainties. The analyst says that the impact of a government shutdown on the sector would be "minor and short-lived," while geopolitical tensions have increased. Publicly traded companies in the space include BAE Systems (BAESY), Boeing (BA), General Dynamics (GD), Lockheed Martin (LMT), Northrop Grumman (NOC), Raytheon (RTN) and United Technologies (UTX).
05/10/17
VERT
05/10/17
UPGRADE
VERT
Buy
Northrop Grumman upgraded to Buy from Hold at Vertical Research
Vertical Research analyst Robert Stallard upgraded Northrop Grumman to Buy from Hold with a $270 price target telling investors defense sector fundamentals remain positive and share underperformance versus peers provides a buying opportunity.
08/08/17
MSCO
08/08/17
INITIATION
Target $279
MSCO
Equal Weight
Northrop Grumman initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated Northrop Grumman with an Equal Weight and a $279 price target saying its leading revenue profile is offset by light free cash flow yields and margin growth.
LLL L3 Technologies
$183.63

0.34 (0.19%)

08/07/17
08/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deere (DE) upgraded to Conviction Buy from Buy at Goldman Sachs. 2. Chemours (CC) upgraded to Neutral from Sell at UBS with analyst John Roberts saying Chemours' execution has disproved his prior concerns. 3. BP (BP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company's cash flow generation is in the early stages of a "multi-year positive inflection" while Macondo headwinds are subsiding. 4. L3 Technologies (LLL) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Nosh Poponak saying he favors increased exposure to Defense given the current industry cycle position, geopolitics, and Department of Defense budget dynamics. 5. Illumina (ILMN) upgraded to Buy from Hold at Canaccord with analyst Mark Massaro saying he sees a strong upgrade cycle for NovaSeq beginning in the tird quarter and lasting for three years. He believes we remain in the early innings on major waves of cancer growth and expects the continuation of robust growth of direct to consumer products, such as 23andMe, ancestry.com and now Helix. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/17
08/08/17
UPGRADE
Target $204

Buy
L3 Technologies upgraded to Buy at Drexel Hamilton
As previously reported, Drexel Hamilton upgraded L3 Technologies and established a $204 price target. Analyst Pete Skibitski is "cautiously" optimistic that there will be a positive resolution in FY18 budget negotiations, which will benefit the entire space, and notes L3's international outlook has improved as the year has progressed.
08/08/17
08/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Hold at Argus with analyst William Selesky saying he expects Tesla to reach breakeven two quarters earlier than he'd previously forecast and sees the company achieving full-year profitability in fiscal 2019. 2. L3 Technologies (LLL) upgraded to Buy from Hold at Drexel Hamilton analyst Pete Skibitski saying he is "cautiously" optimistic that there will be a positive resolution in fiscal 2018 budget negotiations, which will benefit the entire space, and notes L3's international outlook has improved as the year has progressed. 3. Foot Locker (FL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Jay Sole saying he believes share weakness related to investor concerns surrounding share loss to Amazon (AMZN) and brands' own websites has created an "excellent" buying opportunity. 4. UPS (UPS) upgraded to Buy from Neutral at Citi with analyst Christian Wetherbee saying he sees a "clear path" toward double-digit earnings growth returning in 2018. 5. Cognizant (CTSH) upgraded to Buy from Hold at Berenberg with analyst Georgios Kertsos saying the market now considers U.S. immigration policy changes as unlikely, which leaves upside for investors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/17
DRXL
08/08/17
UPGRADE
DRXL
Buy
L3 Technologies upgraded to Buy from Hold at Drexel Hamilton
AET Aetna
$152.15

-0.27 (-0.18%)

07/14/17
PIPR
07/14/17
NO CHANGE
Target $18
PIPR
Overweight
Piper views updated Aetna policy as disappointing for Natera
Piper Jaffray analyst William Quirk views Aetna's (AET) updated non-invasive prenatal testing medical policy, where it decided to continue covering the test only in high risk, as "disappointing." Upside for Natera (NTRA) in the second half of 2017 now falls on Medicaid and microdeletion reimbursement progress, and less so commercial payers flipping to cover average risk, Quick tells investors in a research note. He keeps an Overweight rating on Natera shares with an $18 price target.
06/28/17
SBSH
06/28/17
NO CHANGE
Target $205
SBSH
Buy
Anthem removed from Focus List at Citi
Citi analyst Ralph Giacobbe removed Anthem (ANTM) from his firm's Focus List but keeps a Buy rating on the shares with a $205 price target. The analyst believes some of the upside catalysts have played out. He also added Aetna (AET) to the Focus List.
06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $165
FBCO
Outperform
Aetna price target raised to $165 from $160 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Aetna to $165 from $160 ahead of Q2 results. He reiterates an Outperform rating on the shares.
ANTM Anthem
$189.43

-0.29 (-0.15%)

06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
CNC Centene
$82.14

0.73 (0.90%)

07/11/17
BERN
07/11/17
NO CHANGE
BERN
Centene price target raised to $100 from $85 at Bernstein
Bernstein analyst Lance Wilkes raised his price target on Centene based on his belief that the managed Medicaid market will grow over the long-term, particularly in long-term care. He keeps an Outperform rating on the stock.
07/26/17
PIPR
07/26/17
NO CHANGE
Target $105
PIPR
Overweight
Piper says double down on Centene, ups target to $105
Piper Jaffray analyst Sarah James attributes yesterday's post-earnings pullback in shares of Centene to the macro backdrop and the company's spending bump that she believes fuels the bear concern that constant spending for growth pressures margins. The analyst "strongly" disagrees and believe this is when investors should double down on Centene shares. The company will see the greatest multiple expansion in the group and has the highest potential for earnings upside, James tells investors in a research note. She raised her price target for the shares to $105 from $85 and keeps an Overweight rating on the name.
06/06/17
MSCO
06/06/17
INITIATION
Target $86
MSCO
Overweight
Centene initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Centene with an Overweight and a $86 price target. The analyst thinks the HealthNet acquisition provides diversification and entry planned expansion in Medicare Advantage could offset potential headwinds.
CI Cigna
$174.38

-0.98 (-0.56%)

06/16/17
06/16/17
NO CHANGE

Leerink reiterates view that Cigna could bid for Humana
Leerink analyst Ana Gupte reiterated his views that Cigna (CI) could make a bid Humana (HUM) following Cigna's disclosure that 60% of its Medicare Advantage plans will be in 4-STAR rated plans. The announcement is most positive for Humana (HUM) which is the largest pure play Medicare Advantage name, but also paves the way for Cigna to potentially dievest its legacy HS Medicare Advantage book and bid for Humana.
HNT Health Net

11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
HUM Humana
$249.99

-1.68 (-0.67%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $250
FBCO
Outperform
Humana price target raised to $250 from $245 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $250 from $245 ahead of Q2 results. He reiterates an Outperform rating on the shares.
08/03/17
PIPR
08/03/17
NO CHANGE
Target $280
PIPR
Overweight
Humana price target raised to $280 from $246 at Piper Jaffray
Piper Jaffray analyst Sarah James raised her price target for Humana to $280 saying the company reported a "strong" beat and raise quarter driven by "strong" Medicare Advantage performance and improved cost control. The analyst sees upside to the current share price and keeps an Overweight rating on Humana.
08/03/17
OPCO
08/03/17
NO CHANGE
Target $255
OPCO
Outperform
Humana price target raised to $255 from $236 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Humana to $255 from $236 following "strong results" that were driven by outperformance in Medicare Advantage, and after the company raised 2017 EPS guidance. The analyst reiterates an Outperform rating on the shares.
08/03/17
FBCO
08/03/17
NO CHANGE
Target $260
FBCO
Outperform
Humana price target raised to $260 from $250 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for Humana to $260 from $250 following quarterly results. The analyst reiterates an Outperform rating on the shares.
MOH Molina Healthcare
$58.05

0.52 (0.90%)

06/14/17
LEER
06/14/17
NO CHANGE
Target $80
LEER
Outperform
Molina Healthcare price target raised to $80 from $70 at Leerink
Leerink analyst Ana Gupte raised her price target for Molina Healthcare shares to $80 and remains "bullish" on the name after a call with CFO and interim CEO Joseph White. The analyst says White aligned with her view that the upcoming re-procurement of State Medicaid contracts "does not pose meaningful downside risk." Further, she learned the CEO search is making good progress with an "attractive slate" of senior executives with Managed Care experience. The analyst keeps an Outperform rating on Molina.
07/25/17
LEER
07/25/17
NO CHANGE
Target $80
LEER
Outperform
Leerink remains bullish on Molina Healthcare after job cut announcement
Leerink analyst Ana Gupte continues to have "strong conviction" on Molina Healthcare and reiterates an Outperform rating and a $80 price target after the company's announcement from its interim CEO and CFO Joseph White on the elimination of 1,400 jobs, or 10% of its corporate and health plan workforce. The analyst estimates this could expand margins by over 50 bps or offer 50% net margin expansion and get the company by the end of September to the low end of the stated target of 1.5%-2% net margins.
UNH UnitedHealth
$193.02

0.45 (0.23%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $200
FBCO
Outperform
UnitedHealth price target raised to $200 from $195 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for UnitedHealth to $200 from $195 ahead of Q2 results. He reiterates an Outperform rating on the shares.
07/19/17
UBSW
07/19/17
NO CHANGE
Target $213
UBSW
Buy
UnitedHealth price target raised to $213 from $194 at UBS
UBS analyst A.J. Rice raised his price target on UnitedHealth to $213 from $194 following Q2 earnings. The analyst cited the company's positive outlook to gain market share in both group and individual Medicare Advantage markets along with continued growth assumptions for Optum Rx. Rice reiterated his Buy rating on UnitedHealth shares.
08/11/17
COWN
08/11/17
NO CHANGE
Target $220
COWN
Outperform
UnitedHealth price target raised to $220 from $175 at Cowen
Cowen analyst Christine Arnold raised her price target on UnitedHealth to $220 from $175. The analyst believes the company can achieve its long-term growth targets in 2018, citing Medicare Advantage enrollment growth, operating efficiencies, commercial market penetration, and OptumRx and OptumInsight earnings gains. Arnold reiterated her Outperform rating on UnitedHealth shares.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
WCG WellCare
$172.39

0.36 (0.21%)

06/06/17
MSCO
06/06/17
INITIATION
Target $183
MSCO
Equal Weight
WellCare initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated WellCare with an Equal Weight rating and $183 price target, citing its current valuation.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $163
FBCO
Neutral
WellCare price target raised to $163 from $155 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for WellCare to $163 from $155 ahead of Q2 results. He reiterates a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

ENR

Energizer

$41.24

-0.09 (-0.22%)

18:58
08/21/17
08/21
18:58
08/21/17
18:58
Hot Stocks
Energizer CEO acquires 12,112 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOMB

Home Bancshares

$23.51

0.11 (0.47%)

, SGBK

Stonegate Bank

$46.70

0.34 (0.73%)

18:41
08/21/17
08/21
18:41
08/21/17
18:41
Hot Stocks
Home Bancshares receives regulatory approvals for merger with Stonegate Bank »

Home BancShares (HOMB)…

HOMB

Home Bancshares

$23.51

0.11 (0.47%)

SGBK

Stonegate Bank

$46.70

0.34 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

ADP

ADP

$102.89

-1.52 (-1.46%)

18:32
08/21/17
08/21
18:32
08/21/17
18:32
Periodicals
ADP CEO: Ackman refused to meet because he needed 'leverage,' CNBC says »

After ADP said its board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

TWX

Time Warner

$102.11

0.92 (0.91%)

, SNAP

Snap

$13.58

-0.43 (-3.07%)

18:18
08/21/17
08/21
18:18
08/21/17
18:18
Periodicals
CNN begins streaming daily news show on Snapchat, Reuters reports »

CNN, which is owned by…

TWX

Time Warner

$102.11

0.92 (0.91%)

SNAP

Snap

$13.58

-0.43 (-3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 24

    Aug

  • 13

    Sep

KKR

KKR

18:11
08/21/17
08/21
18:11
08/21/17
18:11
Hot Stocks
Breaking Hot Stocks news story on KKR »

ValueAct raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$34.60

0.62 (1.82%)

18:05
08/21/17
08/21
18:05
08/21/17
18:05
Hot Stocks
Baozun reports Q2 Total Gross Merchandise Volume RMB3.604B »

An increase of 63.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BZUN

Baozun

$34.60

0.62 (1.82%)

18:03
08/21/17
08/21
18:03
08/21/17
18:03
Earnings
Baozun sees Q3 revenue RMB870M-RMB910M »

The company will begin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BZUN

Baozun

$34.60

0.62 (1.82%)

18:02
08/21/17
08/21
18:02
08/21/17
18:02
Earnings
Breaking Earnings news story on Baozun »

Baozun reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

BZUN

Baozun

$34.60

0.62 (1.82%)

18:01
08/21/17
08/21
18:01
08/21/17
18:01
Earnings
Baozun reports Q2 EPS 8c, consensus 10c »

Reports Q2 revenue $131M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

KKR

KKR

18:00
08/21/17
08/21
18:00
08/21/17
18:00
Periodicals
KKR near 'clinching' $3B commitment from NYC pension system, Bloomberg says »

KKR is getting close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESV

Ensco

$4.19

-0.09 (-2.10%)

, NBL

Noble Energy

$23.54

-0.11 (-0.47%)

17:56
08/21/17
08/21
17:56
08/21/17
17:56
Hot Stocks
Ensco awarded contract by Noble Energy »

Ensco (ESV) announced…

ESV

Ensco

$4.19

-0.09 (-2.10%)

NBL

Noble Energy

$23.54

-0.11 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 05

    Oct

GDOT

Green Dot

$46.58

0.31 (0.67%)

17:51
08/21/17
08/21
17:51
08/21/17
17:51
Hot Stocks
Breaking Hot Stocks news story on Green Dot »

Harvest Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RT

Ruby Tuesday

$1.84

-0.06 (-3.16%)

, RIG

Transocean

$7.32

-0.16 (-2.14%)

17:46
08/21/17
08/21
17:46
08/21/17
17:46
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ruby…

RT

Ruby Tuesday

$1.84

-0.06 (-3.16%)

RIG

Transocean

$7.32

-0.16 (-2.14%)

NDSN

Nordson

$125.12

0.99 (0.80%)

FN

Fabrinet

$39.82

-0.26 (-0.65%)

TEDU

Tarena

$18.61

0.59 (3.27%)

ZAYO

Zayo Group

$32.97

-0.08 (-0.24%)

PINC

Premier

$32.78

-0.16 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 29

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Dec

RIG

Transocean

$7.32

-0.16 (-2.14%)

17:41
08/21/17
08/21
17:41
08/21/17
17:41
Hot Stocks
Transocean director acquires 2,000 registered shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

RDN

Radian Group

$16.46

-0.26 (-1.56%)

17:38
08/21/17
08/21
17:38
08/21/17
17:38
Hot Stocks
Radian Group CEO Thornberry buys 15,000 shares »

Radian Group CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RT

Ruby Tuesday

$1.84

-0.06 (-3.16%)

17:38
08/21/17
08/21
17:38
08/21/17
17:38
Earnings
Ruby Tuesday reports Q4 adjusted EPS 6c vs 10c last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 06

    Dec

SRNE

Sorrento Therapeutics

$1.70

-0.05 (-2.86%)

17:29
08/21/17
08/21
17:29
08/21/17
17:29
Hot Stocks
Sorrento closes transactions contemplated by contribution pact with Celularity »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

GPN

Global Payments

$94.57

0.81 (0.86%)

17:24
08/21/17
08/21
17:24
08/21/17
17:24
Hot Stocks
Global Payments Chairman William Jacobs sells 8,428 shares of company stock »

Global Payments Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$267.70

0.09 (0.03%)

17:19
08/21/17
08/21
17:19
08/21/17
17:19
Hot Stocks
Northrop Grumman awarded $328.6M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

BA

Boeing

$235.68

-0.09 (-0.04%)

17:18
08/21/17
08/21
17:18
08/21/17
17:18
Hot Stocks
Boeing awarded $349.2M government contract »

The Boeing Co.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$301.88

2.68 (0.90%)

17:17
08/21/17
08/21
17:17
08/21/17
17:17
Hot Stocks
Lockheed Martin awarded $427M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

PBFX

PBF Logistics

$20.80

-0.05 (-0.24%)

17:11
08/21/17
08/21
17:11
08/21/17
17:11
Hot Stocks
Breaking Hot Stocks news story on PBF Logistics »

Carlos Slim reports 5.1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$48.14

0.45 (0.94%)

17:10
08/21/17
08/21
17:10
08/21/17
17:10
Periodicals
Yahoo owes $5.5M to SCA Promotions after backing out of contract, Reuters says »

The 5th U.S. Circuit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 31

    Aug

  • 06

    Sep

  • 19

    Sep

XOM

Exxon Mobil

$76.38

-0.26 (-0.34%)

17:07
08/21/17
08/21
17:07
08/21/17
17:07
Hot Stocks
Exxon Mobil says fire at a refinery in Botlek, Rotterdam 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

TEAR

TearLab

$1.61

0.01 (0.63%)

17:03
08/21/17
08/21
17:03
08/21/17
17:03
Syndicate
Breaking Syndicate news story on TearLab »

TearLab files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.